RE:RE:RE:RE:RE:RE:RE:RE:RE:This board is getting very quiet. LastHurrah wrote: IF management really wanted a deal then it probably would be done by now.
You are totally right! If they wanted a deal they would have one right now. But they don't just want a deal - they want a good deal. This is the bottom line you guys need to understand, Sernova has their own idea of what their technology is worth and it is multitudes greater than the current share price. Guess what, Big Pharma doesn't care about that. Big Pharma would have a hard time justifying it to their share holders / board members why they overpayed for an experimental high risk technology. Look at other deals, how many have you seen with premiums greater than 100% on the share price? Additionally, these licensing deals almost assuredely have exclusivity terms and are not to be taken lightly.
Also, People talk about how Sernova should have a much higher value now that some of the competition (I'm looking at your Sigilon) has failed. But all it caused is the risk factor to go up in the eyes of large pharma. They've watched a ~1.5 billIon dollar company plummet to a mere 57 million market cap. Pretty scary idea shelling out big bucks when that could be the result.
Finally, you gotta realize that any company who makes a deal with Sernova right now, is about 3 to 5 years away from getting any return on investment. Certainly not too enticing if you ask me. Personnel, I think we are not going to get that big show stopper deal until we prove our immune protection technology. That's the missing piece before Sernova even has a product to sell to these large pharma companies.
Anyway, don't be going around talking like "Oh Management would have a deal done now if they wanted to" because it just makes you sound pretty ignorant to the other, much greater factors at play here.